1. ToxGenSolutions BV identified a 9 miR periferal profile that can identify individuals at risk for acquiring late-onset Alzheimer’s Disease years in advance
28.10.2022
This proposal addresses the objective to drive the development of cutting-edge biomarkers and to explore novel diagnostic technologies.
The ultimate goal of our program is to make diagnosis of late-onset Alzheimer’s Disease (AD):
- faster by turning the months/years it takes for the current diagnostic approach into hours,
- cheaper by eliminating expensive scans (e.g., €2,000-€2,500/$3,000-$4,500 for PET scans),
- more accurate in the prodromal phase of the disease with currently 50% of individuals diagnosed with mild cognitive impairment (MCI) not developing dementia,
- less invasive by replacing CSF sampling with blood sampling (urine as an option).
Our work-hypothesis: Individuals at risk for progressing into AD must be identified early if future drugs (once available) are to have any effect on the quality of life. Thus, novel biomarkers should reflect processes that are in transition from normal physiology into AD related pathology before neurons start to die off and the brain volume shrinks.
Next step: The prognostic profile is currently being validated with the support from the EU EuroStars programme. The product will be a biosensor device providing results within 3 hours after the blood/urine sample was taken, with a 90% accuracy according to the data that emerged from a pilot study.
Outreach: ToxGenSolutions is reaching out to investors and companies active in the field of diagnostics and drug development with the purpose of setting up commercial collaborations.